Get the Stockscreener App
0.2327
1.90%
-0.0045
After Hours:
.23
-0.0027
-1.16%
AIM ImmunoTech Inc stock is traded at $0.2327, with a volume of 5.63M.
It is down -1.90% in the last 24 hours and down -55.01% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.2372
Open:
$0.23
24h Volume:
5.63M
Relative Volume:
0.51
Market Cap:
$3.39M
Revenue:
$88,000
Net Income/Loss:
$-13.96M
P/E Ratio:
-0.035
EPS:
-6.6545
Net Cash Flow:
$-11.34M
1W Performance:
-43.38%
1M Performance:
-55.01%
6M Performance:
-84.57%
1Y Performance:
+145.45%
1-Day Range:
$0.2275
$0.2393
1-Week Range:
$0.21
$0.459
52-Week Range:
$0.21
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.2327 | 3.45M | 88,000 | -13.96M | -11.34M | -6.6545 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM Should I Buy - Intellectia AI
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
AIM ImmunoTech Announces Equity Offering to Bolster Capital - TipRanks
AIM ImmunoTech (NYSE: AIM) offers 7.52M shares; private warrants for 15.04M - Stock Titan
AIM ImmunoTech Raises $2.4M in Registered Direct, Adds $4.9M Warrant Upside at $0.325 - TradingView
AIM ImmunoTech (NYSE: AIM) raises $2.4M via stock sale and warrants - Stock Titan
AIM ImmunoTech prices $2.4M registered direct offering By Investing.com - Investing.com South Africa
AIM ImmunoTech prices $2.4M registered direct offering - Investing.com UK
AIM ImmunoTech announces $2.4M registered direct offering - TipRanks
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct ... - Caledonian Record
Press Release: AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement - 富途牛牛
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech Inc. has officially suspended its equity distribution agreement and will terminate its continuous offering program effective from May 19, 2026. - Bitget
AIM Immunotech (NYSE American: AIM) suspends ATM program after $2.85M sold - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
AIM ImmunoTech Boosts Stockholder Equity by $11.9 Million and Extends Promissory Note to 2027 to Advance Pancreatic Cancer Strategy 12 - Minichart
AIM ImmunoTech extends debt maturity, reports equity gain By Investing.com - Investing.com South Africa
AIM ImmunoTech announces significant increase in stockholder equity and extension of promissory note maturity date to June 2027 - marketscreener.com
Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027 - TradingView
AIM ImmunoTech Strengthens Equity Position and Financial Flexibility - TipRanks
AIM ImmunoTech Inc. announced an extension to the maturity date of one of its promissory notes. - Bitget
AIM ImmunoTech extends debt maturity, reports equity gain - Investing.com
AIM ImmunoTech Extends Streeterville Promissory Note to 2027; Adds $10,000 Fee, $1.68M Balance - TradingView
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities - The Manila Times
AIM ImmunoTech equity jumps $11.9M, debt pushed to 2027 for pancreatic cancer - Stock Titan
Equity swings positive as AIM ImmunoTech (NYSE: AIM) extends note to 2027 - Stock Titan
AIM ImmunoTech Inc. Amends Promissory Note Agreement With Streeterville Capital and Extends Maturity Date to June 30, 2027 - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
12 Health Care Stocks Moving In Monday's After-Market SessionAIM ImmunoTech (AMEX:AIM), Atlantic Inter - Benzinga
$AIM ImmunoTech (AIM.US)$ buy sell flyy🔥 - Moomoo
AIM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AIM ImmunoTech (AIM) posts Q1 2026 loss, flags going concern and NYSE equity shortfall - Stock Titan
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer - Sahm
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment - The National Law Review
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader - GlobeNewswire
AIM ImmunoTech Highlights Ampligen’s Positive Phase 2 Data in Late-Stage Pancreatic Cancer and Survival Benefits - Minichart
AIM ImmunoTech Highlights Ampligen Progress in Pancreatic Cancer - TipRanks
AIM ImmunoTech Reports Positive Data from Named Patient Program and Interim Results from Phase 2 Study of Ampligen® for Late-Stage Pancreatic Cancer - Quiver Quantitative
AIM ImmunoTech (NYSE: AIM) showcases Ampligen pancreatic cancer data in KOL segment - Stock Titan
Pancreatic cancer data show 22.3‑month survival gain with Ampligen - Stock Titan
Earnings Scheduled For May 13, 2026 - Benzinga
AIM ImmunoTech Company Profile & Introduction - Moomoo
AIM ImmunoTech raises $3.6 million through warrant inducement transaction By Investing.com - Investing.com Nigeria
AIM ImmunoTech raises $3.6 million through warrant inducement transaction - Investing.com
AIM ImmunoTech Raises Capital Through Warrant Exercise Inducement - TipRanks
Orca Capital reports 1.79M shares in AIM ImmunoTech (NASDAQ: AIM) - Stock Titan
AIM ImmunoTech (NYSE: AIM) gets $3.6M from warrant exercise inducement deal - Stock Titan
MSN Money - MSN
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):